267 related articles for article (PubMed ID: 27080148)
21. Methods to Make Homogenous Antibody Drug Conjugates.
Kline T; Steiner AR; Penta K; Sato AK; Hallam TJ; Yin G
Pharm Res; 2015 Nov; 32(11):3480-93. PubMed ID: 25511917
[TBL] [Abstract][Full Text] [Related]
22. Linker technologies for antibody-drug conjugates.
Nolting B
Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
[TBL] [Abstract][Full Text] [Related]
23. Antibody-drug conjugates- stability and formulation.
Duerr C; Friess W
Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
[TBL] [Abstract][Full Text] [Related]
24. Antibody-drug conjugates for the treatment of cancer.
Flygare JA; Pillow TH; Aristoff P
Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
26. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
27. Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.
Beck A; Terral G; Debaene F; Wagner-Rousset E; Marcoux J; Janin-Bussat MC; Colas O; Van Dorsselaer A; Cianférani S
Expert Rev Proteomics; 2016; 13(2):157-83. PubMed ID: 26653789
[TBL] [Abstract][Full Text] [Related]
28. The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.
Liu R; Chen X; Dushime J; Bogalhas M; Lazar AC; Ryll T; Wang L
MAbs; 2017 Apr; 9(3):490-497. PubMed ID: 28136017
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the Primary Structure of Cysteine-Linked Antibody-Drug Conjugates Using Capillary Electrophoresis with Mass Spectrometry.
Saadé J; Gahoual R; Beck A; Leize-Wagner E; François YN
Methods Mol Biol; 2020; 2078():263-272. PubMed ID: 31643063
[TBL] [Abstract][Full Text] [Related]
30. Formulation development of antibody-drug conjugates.
Galush WJ; Wakankar AA
Methods Mol Biol; 2013; 1045():217-33. PubMed ID: 23913150
[TBL] [Abstract][Full Text] [Related]
31. Drug-to-antibody determination for an antibody-drug-conjugate utilizing cathepsin B digestion coupled with reversed-phase high-pressure liquid chromatography analysis.
Adamo M; Sun G; Qiu D; Valente J; Lan W; Song H; Bolgar M; Katiyar A; Krishnamurthy G
J Chromatogr A; 2017 Jan; 1481():44-52. PubMed ID: 28017567
[TBL] [Abstract][Full Text] [Related]
32. Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates?
D'Atri V; Pell R; Clarke A; Guillarme D; Fekete S
J Chromatogr A; 2019 Feb; 1586():149-153. PubMed ID: 30554777
[TBL] [Abstract][Full Text] [Related]
33. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
Kaur S; Xu K; Saad OM; Dere RC; Carrasco-Triguero M
Bioanalysis; 2013 Jan; 5(2):201-26. PubMed ID: 23330562
[TBL] [Abstract][Full Text] [Related]
34. Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.
Kraynov E; Kamath AV; Walles M; Tarcsa E; Deslandes A; Iyer RA; Datta-Mannan A; Sriraman P; Bairlein M; Yang JJ; Barfield M; Xiao G; Escandon E; Wang W; Rock DA; Chemuturi NV; Moore DJ
Drug Metab Dispos; 2016 May; 44(5):617-23. PubMed ID: 26669328
[TBL] [Abstract][Full Text] [Related]
35. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates.
Wiggins B; Liu-Shin L; Yamaguchi H; Ratnaswamy G
J Pharm Sci; 2015 Apr; 104(4):1362-72. PubMed ID: 25631158
[TBL] [Abstract][Full Text] [Related]
36. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
37. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
38. Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective.
Dahlgren D; Lennernäs H
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575828
[TBL] [Abstract][Full Text] [Related]
39. Drug Loading and Distribution of ADCs After Reduction or IdeS Digestion and Reduction.
Wagner-Rousset E; Colas O; François YN; Heinisch S; Guillarme D; Cianférani S; Beck A
Methods Mol Biol; 2020; 2078():187-195. PubMed ID: 31643057
[TBL] [Abstract][Full Text] [Related]
40. Native-MS Analysis of Monoclonal Antibody Conjugates by Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.
Campuzano IDG; Netirojjanakul C; Nshanian M; Lippens JL; Kilgour DPA; Van Orden S; Loo JA
Anal Chem; 2018 Jan; 90(1):745-751. PubMed ID: 29193956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
